原著論文(英文)

  1. Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies).                              
    Ono R, Nakayama K, Nakamura K, Yamashita H, Ishibashi T, Ishikawa M, Minamoto T, Razia S, Ishikawa N, Otsuki Y, Nakayama S, Onuma H, Kurioka H, Kyo S.
    Int J Mol Sci. 2019; 31;20. pii: E3744.
  2. Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas.
    Razia S, Nakayama K, Nakamura K, Ishibashi T, Ishikawa M, Minamoto T, Iida K, Otsuki Y, Nakayama S, Ishikawa N, Kyo S.
    Exp Ther Med. 2019; 18:2278-2284.
  3. Role of activin, follistatin, and inhibin in the regulation of Kiss-1 gene expression in hypothalamic cell models. 
    Tumurgan Z, Kanasaki H, Tumurbaatar T, Oride A, Okada H, Hara T, Kyo S.
    Biol Reprod. 2019; 101:405-415.
  4. Role of RFRP-3 in the Regulation of Kiss-1 Gene Expression in the AVPV Hypothalamic Cell Model mHypoA-50.
    Kanasaki H, Tumurbaatar T, Oride A, Tumurgan Z, Okada H, Hara T, Tsutsui K, Kyo S.
    Reprod Sci. 2019; 26:1249-1255.
  5. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
    Ishikawa M, Nakayama K, Nakamura K, Ono R, Yamashita H, Ishibashi T, Minamoto T, Iida K, Razia S, Ishikawa N, Kyo S.
    Hum Pathol. 2019; 85:92-100.
  6. Effect of pituitary adenylate cyclase-activating polypeptide (PACAP) in the regulation of hypothalamic kisspeptin expression.
    Tumurbaatar T, Kanasaki H, Oride A, Okada H, Hara T, Tumurgan Z, Kyo S.
    Gen Comp Endocrinol. 2019; 270:60-66.
  7. Role of kisspeptin and Kiss1R in the regulation of prolactin gene expression in rat somatolactotroph GH3 cells.
    Hara T, Kanasaki H, Tumurbaatar T, Oride A, Okada H, Kyo S.
    Endocrine. 2019; 63:101-111.
  8. Effect of relaxin-3 on Kiss-1, gonadotropin-releasing hormone, and gonadotropin subunit gene expression.
    Kanasaki H, Tumurbaatar T, Tumurgan Z, Oride A, Okada H, Kyo S.
    Reprod Med Biol. 2019;18:397-404. 
  9. Postoperative Outcomes Following Tension-Free Vaginal Mesh Surgery for Pelvic Organ Prolapse: A Retrospective Study.
    Oride A, Kanasaki H, Hara T, Kyo S.
    Urol J. 2019;16:581-585.
  10. Sarcopenic Factors May Have No Impact on Outcomes in Ovarian Cancer Patients.
    Nakayama N, Nakayama K, Nakamura K, Razia S, Kyo S.
    Diagnostics. 2019;9.pii: E206. doi: 10.3390/diagnostics9040206.
  11. High Frequency of PIK3CA Mutations in Low-Grade Serous Ovarian Carcinomas of Japanese Patients.
    Ishibashi T, Nakayama K, Razia S, Ishikawa M, Nakamura K, Yamashita H, Dey P, Iida K, Kurioka H, Nakayama S, Otsuki Y, Ishikawa N, Kyo S.
    Diagnostics. 2019 ;10. pii: E13. doi: 10.3390/diagnostics10010013.
  12. Prolactin Enhances the Proliferation of Proliferative Endometrial Glandular Cells and Endometrial Cancer Cells.
    Yamaguchi M, Erdenebaatar C, Saito F, Honda R, Ohba T, Kyo S, Tashiro H, Katabuchi H.
    J Endocr Soc. 2019;4:bvz029. doi: 10.1210/jendso/bvz029.
  13. Relationship Between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future.
    Yamashita H, Nakayama K, Ishikawa M, Ishibashi T, Nakamura K, Sawada K, Yoshimura Y, Tatsumi N, Kurose S, Minamoto T, Iida K, Razia S, Ishikawa N, Kyo S.
    Int.J.Mol Sci. 2019;20:512. doi: 10.3390/ijms20205129.
  14. Fatal Postpartum Hemorrhage in Diffuse Midline Glioma with H3-K27M Mutation.
    Miyazaki T, Tsuji M, Hagiwara S, Minamoto T, Ishikawa N, Hirato J, Nobusawa S, Akiyama Y.
    Case Rep Obstet Gynecol. 2019 Aug 21;2019:8340437. doi: 10.1155/2019/8340437. eCollection 2019.